| アブストラクト | Antimicrobial stewardship is an activity that optimizes patient care through selection of the most appropriate antimicrobial therapy. Antimicrobial stewardship programs strive to enhance patient care and reduce preventable consequences of antimicrobial use. They are also vital in monitoring for the development of adverse events occurring as a result of antimicrobial therapy, although literature reviews of this activity are scarce. Although randomized controlled trials are considered the gold standard to study the efficacy of a medication, these trials are not designed to test safety end points and often are only able to identify the most commonly occurring and acute adverse events. In addition, prior to a drug going to market, it is difficult to detect rare adverse events because the associated costs are economically untenable given the limited pipeline of novel agents. These limitations in some ways may be resolved with the use of postmarketing surveillance and spontaneous reporting systems such as the United States Food and Drug Administration Adverse Event Reporting System. The focus of this commentary is to highlight the importance of adverse event reporting by antimicrobial stewardship programs to spontaneous reporting systems as a means to improve patient care. |
|---|
| ジャーナル名 | Pharmacotherapy |
|---|
| Pubmed追加日 | 2015/01/24 |
|---|
| 投稿者 | Hoffmann, Charles; Khadem, Tina; Schweighardt, Anne; Brown, Jack |
|---|
| 組織名 | Department of Pharmacy, University of Rochester Medical Center, Rochester, New;York. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/25615401/ |
|---|
